HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...
This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...
Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...
On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.
NEW YORK – Context Therapeutics on Wednesday said it began treating patients in a Phase I trial of its claudin 6 (CLDN6)- and CD3 T-cell-engaging bispecific antibody, CTIM-76, in CLDN6-positive ...
The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...